To demonstrate the utility of NEC PDX models as a potential tool for testing receptor-targeted theranostics, we conducted a proof-of-concept study whereby we established a mouse model with tumor implantations using the NEC913 (SSTR2+) and NEC1452 (SSTR2−) cells in opposite shoulders for SSTR2-targeted imaging (Figure 4A). The gene discussed is SSTR2; the disease is neuroendocrine carcinoma.